SCREEN FOR G6PD DEFICIENCY PRIOR TO THE FIRST INFUSION
See why it is imperative to screen for G6PD deficiency prior to infusing KRYSTEXXA, and what to do based on the screening results.
PRIOR TO THE FIRST INFUSION: CONFIRM THE SCREENING RESULTS FOR G6PD DEFICIENCY
KRYSTEXXA is contraindicated in patients with G6PD deficiency1,2
- G6PD-deficient patients may experience life-threatening hemolytic reactions and methemoglobinemia
- It is important to test patients for G6PD deficiency prior to initiating treatment because they often appear asymptomatic and will likely not be aware of this deficiency
WHAT IS G6PD DEFICIENCY?
G6PD deficiency is a genetic disorder that causes red blood cells to break down prematurely or in response to certain medications, including KRYSTEXXA. It is the most common enzyme deficiency disorder of red blood cells worldwide.3,4
WHO IS AT THE GREATEST RISK?
G6PD deficiency is the most common enzyme deficiency disorder of red blood cells, affecting 400 million people worldwide. G6PD predominantly affects males, particularly those of African, Mediterranean, or Asian ancestry.4,5
WHEN DO I SCREEN MY PATIENTS?
Unlike the serum uric acid (sUA) test, which should be performed prior to each infusion, the G6PD deficiency screening should be conducted one time, prior to the first infusion.1*
HOW DO I SCREEN MY PATIENTS?*
Perform a standard blood draw for lab analysis. Either a qualitative or quantitative screening can be ordered to determine G6PD deficiency.5
HOW DO I INTERPRET SCREENING RESULTS?
|Screening Classification Normal Quantitative Value OR Negative Qualitative Result for Deficiency||Interpretation Patient Does Not Have G6PD Deficiency||Recommendation1 Can Proceed to Treatment With KRYSTEXXA as Indicated|
|Screening Classification Low Quantitative Value OR Positive Qualitative Result for Deficiency||Interpretation Patient May Have G6PD Deficiency†||
Do Not Administer KRYSTEXXA to
Patients With G6PD Deficiency
If you have general questions regarding screening for G6PD deficiency, please call Medical Information at 1-866-479-6742
*Because the test results are typically returned within 2 to 3 days, G6PD screening is recommended at the time of service request form submission, or as early as possible.
†Acute hemolytic anemia, which may be the result of the patient’s medications, can produce inaccurate results. Additionally, if a patient has received a blood transfusion in the past 90 days, the transfusion could alter the test results. For either of these situations, postpone testing or consider retesting in 2 to 3 months.2,4
- KRYSTEXXA (pegloticase) [prescribing information] Horizon.
- Belfield KD, et al. Am J Health Syst Pharm. 2018;75:e69-e76.
- Genetics Home Reference. https://ghr.nlm.nih.gov/condition/glucose-6-phosphate-dehydrogenase-deficiency. Accessed May 14, 2019.
- Minucci A, et al. IUBMB Life. 2009;61:27-34.
- Frank JE. Am Fam Physician. 2005;72:1277-1282.